The clinical rationale is well-supported: if an algorithm can reliably predict epidermal growth factor receptor (EGFR) or Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation status from a slide that every pathology laboratory already produces, the implications for treatment access in resource-limited settings are practically significant.
← all excerpts
Artificial intelligence in thoracic surgery: a narrative review of clinical advances and applications in 2025.
1
—
—